These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 16003296

  • 1. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase.
    Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y.
    Clin Pharmacol Ther; 2005 Jul; 78(1):81-8. PubMed ID: 16003296
    [Abstract] [Full Text] [Related]

  • 2. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [Abstract] [Full Text] [Related]

  • 3. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y.
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [Abstract] [Full Text] [Related]

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
    Ghio L, Ferraresso M, Viganò SM, Ginevri F, Perfumo F, Gianoglio B, Murer L, Zacchello G, Dello Strologo L, Cardillo M, Tirelli S, Valente U, Edefonti A.
    Transplant Proc; 2005 Mar; 37(2):856-8. PubMed ID: 15848555
    [Abstract] [Full Text] [Related]

  • 10. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G, Foster J, Berard R, Mai I, Lepage N.
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [Abstract] [Full Text] [Related]

  • 11. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N.
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [Abstract] [Full Text] [Related]

  • 12. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.
    Kuypers DR.
    Drugs Aging; 2009 Feb; 26(9):715-37. PubMed ID: 19728747
    [Abstract] [Full Text] [Related]

  • 14. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of mycophenolate mofetil and sirolimus in children.
    Filler G, Bendrick-Peart J, Christians U.
    Ther Drug Monit; 2008 Apr; 30(2):138-42. PubMed ID: 18367972
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K.
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [Abstract] [Full Text] [Related]

  • 17. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
    Tönshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DR, Tsai E, Vinks AA, Weber LT, Zimmerhackl LB.
    Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
    [Abstract] [Full Text] [Related]

  • 18. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, Habuchi T.
    Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
    [Abstract] [Full Text] [Related]

  • 19. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
    Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W.
    Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
    [Abstract] [Full Text] [Related]

  • 20. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation.
    Filler G.
    Pediatr Transplant; 2006 Sep; 10(6):707-11. PubMed ID: 16911495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.